SCHEDULE: Squadron Funds Report 7.0% Stake in Relmada Therapeutics

Squadron Master Fund LP, along with its investment advisor and partners, has reported beneficial ownership of 7.0% of Relmada Therapeutics, Inc. common stock.

Summary

• Squadron Master Fund LP, through its investment advisor Squadron Capital Management, LLC, and partners Matthew Sesterhenn and William Blank, has disclosed beneficial ownership of 7,350,000 shares of Relmada Therapeutics, Inc. common stock.
• This holding represents 7.0% of the company's outstanding common stock.
• The filing is an amendment (Amendment No. 3) to a Schedule 13G.
• The reporting persons disclaim beneficial ownership beyond their pecuniary interest.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without indicating new strategic investments or significant shifts in the company's operational or financial trajectory.

Positives

• Significant institutional ownership reported, indicating investor interest in Relmada Therapeutics.
• The filing clearly states the percentage of ownership (7.0%), providing transparency to the market.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Relmada Therapeutics.
• The reporting persons expressly disclaim beneficial ownership beyond their pecuniary interest, which could imply a lack of direct control or strategic intent beyond investment.

Risks

• Potential for increased share price volatility due to the significant stake held by an institutional investor.
• Future actions by Squadron Master Fund LP, such as further accumulation or divestment, could impact the stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Relmada Therapeutics' future performance.

Management Comments

• Squadron Capital Management, LLC, which serves as investment adviser to private funds, including but not limited to Squadron Master Fund LP (collectively, the 'Funds'), may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Mr. Sesterhenn and Mr. Blank, as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Funds.
• Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Squadron Capital Management, LLC or Mr. Sesterhenn and Mr. Blank are the beneficial owner of any of the securities reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Squadron Master Fund LP's substantial investment in Relmada Therapeutics, a biotechnology company, aligning with typical investment patterns in the sector.

Stakeholder Impact

• Shareholders: Increased institutional ownership may influence stock liquidity and price discovery. The disclaimers of beneficial ownership might raise questions about the extent of control or influence by the reporting persons.
• Management: May need to engage with Squadron Master Fund LP regarding their investment strategy and potential influence.
• Potential Investors: The filing provides transparency on a significant shareholder, aiding in investment analysis.

Next Steps

• Monitor future filings from Squadron Master Fund LP for any changes in beneficial ownership.
• Observe Relmada Therapeutics' operational and financial performance for insights into the investment thesis.

Key Dates

Keywords

Relmada Therapeutics, Squadron Master Fund LP, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Advisor